“Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials”, J of Skin, vol. 5, no. 1, p. s21, Jan. 2021, doi: 10.25251/skin.5.supp.21.